Clinical data | |
---|---|
Trade names | Odomzo |
Other names | LDE225, erismodegib |
AHFS/Drugs.com | Monograph |
MedlinePlus | a615034 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Antineoplastic agents |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | <10% |
Protein binding | >97% |
Metabolism | Liver (CYP3A) |
Elimination half-life | ~28 days |
Excretion | Feces (~70%), urine (30%)[1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C26H26F3N3O3 |
Molar mass | 485.507 g·mol−1 |
3D model (JSmol) | |
| |
|
Sonidegib (INN), sold under the brand name Odomzo, is a medication used to treat cancer.[1]
Sonidegib is Hedgehog signaling pathway inhibitor (via smoothened antagonism).[5][6]
It was approved for medical use in the United States and in the European Union in 2015[7][1][8][9]
It is indicated for the treatment of adults with locally advanced basal-cell carcinoma that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.[1]
Sonidegib is administered by mouth. Common side effects include muscle spasms, hair loss, fatigue, abdominal pain, nausea, headache, and weight loss.[1]
Sonidegib binds to and inhibits smoothened to inhibit activation of the Hedgehog pathway. Sonidegib is primarily metabolized by CYP3A and is eliminated hepatically.[1]
It has been investigated as a potential treatment for:
It has demonstrated significant efficacy against melanoma in vitro and in vivo.[28] It also demonstrated efficacy in a mouse model of pancreatic cancer.[29]